newsfilter
← Latest News
GlobeNewswire·

MediciNova to Participate in Two Investor Conferences in September

  • MediciNova, Inc. President & CEO Yuichi Iwaki & Chief Business Officer David Crean will attend two investor conferences in September 2026.
  • The company will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel from September 14-16, featuring virtual presentations starting September 11.
  • Management will join the ROTH Capital 5th Annual Healthcare Opportunities Conference on September 29 at The Metropolitan Club in New York City for a panel on "Frontiers in Neuroscience" & investor meetings.
  • Dr. Iwaki expects top-line data from the Phase 2 MN-001-NATG-202 study in metabolic disease by the end of Q3 2026.
  • A top-line readout from the double-blind phase of the COMBAT-ALS study for MN-166 is anticipated by year-end 2026.
  • MediciNova reports a cash position of $25.4 million as of Q2 2026 to fund operations & business milestones.
  • The company's lead asset MN-166 (ibudilast) is in Phase 3 trials for ALS & degenerative cervical myelopathy, with Phase 3 readiness for progressive multiple sclerosis.
  • MN-166 is also under evaluation in Phase 2 trials for Long COVID & substance dependence.
  • MN-001 (tipelukast) completed a Phase 2 trial in idiopathic pulmonary fibrosis & is currently in a second Phase 2 trial for non-alcoholic fatty liver disease.